Company Overview - Liquidia is a biopharmaceutical company focused on innovative therapies for pulmonary arterial hypertension, utilizing proprietary drug delivery technologies [6] - The company's strategy aims to address unmet medical needs through differentiated product formulations and expanding its portfolio in the U.S. market [6] - Liquidia's competitive advantage lies in its specialized expertise in inhaled drug delivery and its ability to commercialize both branded and generic therapies within a highly regulated sector [6] Financial Performance - As of February 17, 2026, Liquidia's stock price was $33.84, reflecting a 105.7% increase over the past year, significantly outperforming the S&P 500 by 97.0 percentage points [3] - The company's market capitalization is $2.94 billion, with a revenue of $69.22 million and a net income of -$121.85 million for the trailing twelve months (TTM) [4] Recent Transactions - Opaleye Management Inc. sold 180,000 shares of Liquidia during the fourth quarter of 2025, with an estimated trade value of approximately $5.12 million based on quarterly average pricing [2] - Following the sale, Opaleye Management holds 2,435,000 shares of Liquidia, with the quarter-end value of the stake increasing by $25.52 million due to trade activity and stock appreciation [2] Investment Position - Liquidia now accounts for 11.21% of Opaleye Management's reportable assets under management (AUM) [3] - Other top holdings of Opaleye Management include NASDAQ:HROW at $191.34 million (25.2% of AUM) and NASDAQ:ETON at $48.36 million (6.4% of AUM) [8]